FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779181106> ?p ?o ?g. }

• W2779181106 endingPage "11815" @default.
• W2779181106 startingPage "11805" @default.
• W2779181106 abstract "Tyrosine kinase inhibition of the epidermal growth factor receptor (EGFR) is the standard in the first line treatment of patients with advanced non-small-cell lung cancer (NSCLC) harbouring EGFR activating mutations. Here we aim to discern efficacy and toxicity measures through a meta-analysis of published studies that could aid treatment selection.We performed a meta-analysis of the main randomized clinical trials evaluating the currently approved EGFR-TKIs in first-line of treatment of EGFR-positive advanced NSCLC. Cochrane guidelines were used for statistical analysis.3,179 patients were included. All EGFR TKIs showed improved outcomes with respect to ORR and PFS when compared to standard platinum-doublet chemotherapy. Comparative ORR for gefitinib, erlotinib and afatinib were 52.1%, 67.3% and 61.6% respectively. HRs for PFS were 0.62 (95% CI, 0.38-1.00) for gefitinib, 0.28 (95% CI, 0.17-0.45) for erlotinib and 0.40 (95% CI, 0.20-0.83) for afatinib. HRs for OS were not statistically significant for any agent.Our results suggest similar clinical efficacy and higher toxicity of Afatinib treatment. As this still remains the agent with best CSF penetration, we suggest its use is limited to patients presenting with brain metastasis. We suggest the use of Gefitinib in patients without CNS involvement. Faced with the impossibility to dose-reduce Gefitinib, Erlotinib represents a tolerable and effective alternative to Afatinib and Gefitinib if response to EGFR inhibition is considered still effective." @default.
• W2779181106 created "2018-01-05" @default.
• W2779181106 creator A5015356197 @default.
• W2779181106 creator A5038704798 @default.
• W2779181106 creator A5044610238 @default.
• W2779181106 creator A5054555867 @default.
• W2779181106 creator A5068401391 @default.
• W2779181106 creator A5081800814 @default.
• W2779181106 creator A5090057211 @default.
• W2779181106 date "2017-12-23" @default.
• W2779181106 modified "2023-10-01" @default.
• W2779181106 title "Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis" @default.
• W2779181106 cites W1518930887 @default.
• W2779181106 cites W1523413020 @default.
• W2779181106 cites W1757407923 @default.
• W2779181106 cites W1938449115 @default.
• W2779181106 cites W1974400937 @default.
• W2779181106 cites W1984047229 @default.
• W2779181106 cites W2065350134 @default.
• W2779181106 cites W2093583166 @default.
• W2779181106 cites W2096198395 @default.
• W2779181106 cites W2110466017 @default.
• W2779181106 cites W2111662961 @default.
• W2779181106 cites W2122553809 @default.
• W2779181106 cites W2129360604 @default.
• W2779181106 cites W2130702804 @default.
• W2779181106 cites W2132157071 @default.
• W2779181106 cites W2133149289 @default.
• W2779181106 cites W2139248078 @default.
• W2779181106 cites W2144330816 @default.
• W2779181106 cites W2152905269 @default.
• W2779181106 cites W2153477391 @default.
• W2779181106 cites W2154662831 @default.
• W2779181106 cites W2160982674 @default.
• W2779181106 cites W2166084034 @default.
• W2779181106 cites W2171139285 @default.
• W2779181106 cites W2286158735 @default.
• W2779181106 cites W2337836619 @default.
• W2779181106 cites W2339311613 @default.
• W2779181106 cites W2398368047 @default.
• W2779181106 cites W2462255669 @default.
• W2779181106 cites W2479121739 @default.
• W2779181106 cites W2484071785 @default.
• W2779181106 cites W4238604577 @default.
• W2779181106 doi "https://doi.org/10.18632/oncotarget.23668" @default.
• W2779181106 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5837761" @default.
• W2779181106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29545937" @default.
• W2779181106 hasPublicationYear "2017" @default.
• W2779181106 type Work @default.
• W2779181106 sameAs 2779181106 @default.
• W2779181106 citedByCount "9" @default.
• W2779181106 countsByYear W27791811062018 @default.
• W2779181106 countsByYear W27791811062019 @default.
• W2779181106 countsByYear W27791811062020 @default.
• W2779181106 countsByYear W27791811062022 @default.
• W2779181106 crossrefType "journal-article" @default.
• W2779181106 hasAuthorship W2779181106A5015356197 @default.
• W2779181106 hasAuthorship W2779181106A5038704798 @default.
• W2779181106 hasAuthorship W2779181106A5044610238 @default.
• W2779181106 hasAuthorship W2779181106A5054555867 @default.
• W2779181106 hasAuthorship W2779181106A5068401391 @default.
• W2779181106 hasAuthorship W2779181106A5081800814 @default.
• W2779181106 hasAuthorship W2779181106A5090057211 @default.
• W2779181106 hasBestOaLocation W27791811061 @default.
• W2779181106 hasConcept C121608353 @default.
• W2779181106 hasConcept C126322002 @default.
• W2779181106 hasConcept C143998085 @default.
• W2779181106 hasConcept C170493617 @default.
• W2779181106 hasConcept C2776256026 @default.
• W2779181106 hasConcept C2778087573 @default.
• W2779181106 hasConcept C2778164965 @default.
• W2779181106 hasConcept C2779013556 @default.
• W2779181106 hasConcept C2779438470 @default.
• W2779181106 hasConcept C2780580887 @default.
• W2779181106 hasConcept C2780586478 @default.
• W2779181106 hasConcept C2909325608 @default.
• W2779181106 hasConcept C42362537 @default.
• W2779181106 hasConcept C71924100 @default.
• W2779181106 hasConcept C98274493 @default.
• W2779181106 hasConceptScore W2779181106C121608353 @default.
• W2779181106 hasConceptScore W2779181106C126322002 @default.
• W2779181106 hasConceptScore W2779181106C143998085 @default.
• W2779181106 hasConceptScore W2779181106C170493617 @default.
• W2779181106 hasConceptScore W2779181106C2776256026 @default.
• W2779181106 hasConceptScore W2779181106C2778087573 @default.
• W2779181106 hasConceptScore W2779181106C2778164965 @default.
• W2779181106 hasConceptScore W2779181106C2779013556 @default.
• W2779181106 hasConceptScore W2779181106C2779438470 @default.
• W2779181106 hasConceptScore W2779181106C2780580887 @default.
• W2779181106 hasConceptScore W2779181106C2780586478 @default.
• W2779181106 hasConceptScore W2779181106C2909325608 @default.
• W2779181106 hasConceptScore W2779181106C42362537 @default.
• W2779181106 hasConceptScore W2779181106C71924100 @default.
• W2779181106 hasConceptScore W2779181106C98274493 @default.
• W2779181106 hasIssue "14" @default.
• W2779181106 hasLocation W27791811061 @default.
• W2779181106 hasLocation W27791811062 @default.
• W2779181106 hasLocation W27791811063 @default.

• next